Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
Clinical trial NCT06688656 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06688656
- Sponsor
- Shanghai Chest Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-31
- Primary completion
- 2026-03-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.